The US FDA is expected to approve the JenaValve Trilogy System, a transcatheter aortic valve replacement (TAVR) device specifically designed to treat aortic regurgitation (AR), a condition where the aortic valve fails to close properly, leading to blood leakage back into the heart, by late 2025. This milestone approval will address a long-standing gap in minimally invasive treatment options for AR, according to GlobalData, a leading data and analytics company.

Since receiving FDA approval for treating aortic stenosis (AS), the TAVR market has experienced an aggressive compound annual growth rate (CAGR) of 17% in value between 2015 and 2024. While TAVR has primarily been utilized for AS, AR represents a significant, underserved market segment. The JenaValve Trilogy System, specifically designed to anchor securely in non-calcified valves—characteristic of AR—demonstrated a procedural success rate exceeding 95% in clinical trials, including the pivotal ALIGN-AR trial.

Joselia Carlos, Senior Medical Device Analyst at GlobalData, comments: “The FDA approval of the JenaValve Trilogy System is a pivotal moment for the TAVR market. The development reflects the growing adaptability of TAVR technology and its potential to improve outcomes for diverse patient populations. It opens up a new avenue for treating AR patients, who have historically had limited options. This innovation highlights the progress of structural heart interventions in addressing unmet clinical needs.”

The value of the TAVR market, driven by its current use for AS alone, is projected to grow at a CAGR of 8% over 2024-34. However, with the inclusion of AR as a new indication, the market is expected to expand further, with growth accelerating to double digits. This trend aligns with the increasing demand for minimally invasive therapies, especially among aging populations and patients with comorbidities who are unsuitable for traditional surgical procedures.

Carlos continues: “The addition of AR to TAVR indications positions the technology as a more comprehensive solution for heart valve diseases. As adoption grows, new iterations of TAVR devices will further enhance outcomes and procedural success.”

The anticipated approval of devices like the Trilogy System highlights a broader trend of innovation in structural heart care, where targeted solutions are expanding treatment options for complex conditions. As more tailored devices enter the market, patient outcomes will likely improve further.

Carlos concludes: “This is just the beginning of a new chapter in structural heart therapy, with significant potential to redefine how valvular diseases are treated. The Trilogy system not only transforms clinical outcomes but also expands access to TAVR treatments for patients who were previously considered untreatable.”